Medical Gastroenterology is integral to the WDDC and was graded 5* (the top grade) in the last research assessment exercise.
We employ a broad range of research methodologies. We have experts in basic and translational research who use cutting-edge molecular biological, cell biological and microbiological techniques. We perform ex vivo research on human tissue using a range of modern technologies. We have facilities for detailed patient-based physiological, therapeutic and imaging research. We perform local clinical trials and co-ordinate national and international multi-centre studies. Finally we have a leading GI epidemiology unit which adds a unique angle to our research approach.
Research interests incorporate virtually all of GI clinical research. We have a leading therapeutics programme, focussing recently on development of safe non-steroidal anti-inflammatory drugs and on the chemotherapeutic potential of these and related compounds. We have a large basic and clinical research programme in inflammatory bowel disease. Neurogastroenterology is a major interest, particularly the genesis of symptoms in irritable bowel syndrome and the development of new diagnostics and treatments. In collaboration with the Sir Peter Mansfield MRI Centre, we research novel imaging of the bowel and visceral pain and taste pathways in the brain. We also develop new endoscopy imaging techniques and new therapeutic strategies. Several of our investigators lead programmes in GI infections, including the ulcer and stomach cancer-causing bacterium Helicobacter pylori and the hospital acquired pathogen Clostridium difficile. We are particularly interested in chemotherapeutic approaches to prevent GI cancers and in developing rational screening and surveillance programmes. Recently we have started a large programme of GI stem cell research. Finally, we have a major interest in hepatology, in particular in hepatitis C infection, the 'new' disease of non-alcoholic fatty liver and the effects of drugs on the liver.